<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ESTROPIPATE</span><br/>(es-troe-pi'pate)<br/><span class="topboxtradename">Ogen, </span><span class="topboxtradename">Ortho-Est<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">estrogen</span><br/><b>Prototype: </b>Estradiol<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.625 mg, 1.25 mg, 2.5 mg, 5 mg tablets; 1.5 mg/g cream</p>
<h1><a name="action">Actions</a></h1>
<p>Water-soluble preparation of pure crystalline estrone (responsible for therapeutic actions).</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Binds to intracellular receptors that stimulate DNA and RNA to synthesize proteins responsible for effects of estrogen.</p>
<h1><a name="uses">Uses</a></h1>
<p>Atrophic vaginitis, kraurosis vulvae, and abnormal bleeding (hormonal imbalance); also female hypogonadism, primary ovarian
         failure, vasomotor symptoms associated with menopause, and as palliative therapy of prostatic carcinoma.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Estrogen hypersensitivity; breast cancer; known or suspected pregnancy (category X); lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypertension; gallbladder disease; diabetes mellitus; heart failure; liver or kidney dysfunction; history of thromboembolic
         disease.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Menopause, Atrophic Vaginitis, Kraurosis Vulvae</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.756 mg/d for 21 d each month; adjust to lowest level that gives symptom control <span class="rdroute">Intravaginal</span> 24 g of cream once/d in a cyclic regimen<br/><br/><span class="indicationtitle">Female Hypogonadism, Primary Ovarian Failure, Female Castration</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1.59 mg/d in 13 divided doses for 21 d, followed by an 810-d drug-free period<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with food or fluid of patient's choice.</li>
</ul><span class="adminroutetype">Intravaginal</span><br/><ul>
<li>Apply vaginal cream using calibrated dosage applicator dispensed with drug. Squeeze tube of cream to force sufficient amount
            into applicator so that number on plunger indicating prescribed dose is level with top of barrel.
         </li>
<li>Store at 15°30° C (59°86° F) in tightly closed containers unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, dizziness, depression, <span class="speceff-common">libido changes.</span> <span class="typehead">CV:</span> <span class="speceff-life">Thromboembolic disorders</span>, edema, hypertension. <span class="typehead">GI:</span> <span class="speceff-common">Nausea,</span> vomiting, diarrhea, bloating, cholestatic jaundice. <span class="typehead">Urogenital:</span> Mastodynia, spotting, changes in menstrual flow, dysmenorrhea, amenorrhea. <span class="typehead">Metabolic:</span> Reduced carbohydrate tolerance, fluid retention. <span class="typehead">Other:</span> Leg cramps, intolerance to contact lenses. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Carbamazepine,</b> <b>phenytoin,</b> <b>rifampin</b> decrease estrogen levels because they increase its metabolism; may enhance steroid effects of <span class="classification">corticosteroids</span>; may decrease anticoagulant effects of <span class="classification">oral anticoagulants</span>.  <span class="typehead">Herbal:</span> <b>St. John's wort</b> may decrease blood levels. <b>Dong quai,</b> <b>red clover,</b> <b>black cohosh,</b> and <b>saw palmetto</b> may have additive hormonal effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Absorbed with some metabolism occuring in GI tract. Some systemic absorption from vaginal administration. <span class="typehead">Metabolism:</span> Metabolized in GI tract and liver. <span class="typehead">Half-Life:</span> 418.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>See nursing implications under estradiol.</li>
<li>Monitor for and report breakthrough vaginal bleeding.</li>
<li>Assess for relief of menopausal symptoms.</li>
<li>Lab tests: Monitor serum phosphatase levels with prostate cancer.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not use tampons while on vaginal cream therapy.</li>
<li>Intravaginal administration: For self-administration, wash hands well before and after application, and avoid contact of denuded
            areas with the cream.
         </li>
<li>Do not use tampons while on vaginal cream therapy. Pull plunger out of barrel and wash applicator in warm soapy water after
            use. Do not place plunger in hot or boiling water.
         </li>
<li> 							Note: Sudden discontinuation of vaginal cream after high dosage or prolonged use may evoke withdrawal bleeding. 						</li>
<li>Review patient package insert (PPI).</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>